FDA Okays TMS Device for Rapid Treatment of Major Depression

The US Food and Drug Administration (FDA) has cleared the next-generation NeuroStar Advanced Therapy transcranial magnetic stimulation (TMS) device for patients with treatment-resistant major depressive disorder (MDD), the company has announced.

“We have widespread insurance reimbursement from most commercial and government health plans, and a next-generation NeuroStar Advanced Therapy that uses proprietary technology and a 19-minute treatment that allows patients to get in and out before work or during their lunch hour,” NeuroStar President and CEO Chris Thatcher said in the release.

Research has shown that TMS can provide lasting relief of antidepressant-resistant MDD and improved quality of life for patients.

To read the complete Medscape article, click here